Latest Phase II results validate Circassia's cat allergy treatment
This article was originally published in Scrip
Executive Summary
Circassia, the specialty biopharmaceutical company based in the UK and developing a new class of T cell vaccines to treat allergies and combat organ transplant rejection, has reported another set of positive results from Phase II trials with its lead R&D programme, the ToleroMune cat allergy treatment.